JP2024515215A - 抗菌剤及び抗癌剤 - Google Patents

抗菌剤及び抗癌剤 Download PDF

Info

Publication number
JP2024515215A
JP2024515215A JP2023565466A JP2023565466A JP2024515215A JP 2024515215 A JP2024515215 A JP 2024515215A JP 2023565466 A JP2023565466 A JP 2023565466A JP 2023565466 A JP2023565466 A JP 2023565466A JP 2024515215 A JP2024515215 A JP 2024515215A
Authority
JP
Japan
Prior art keywords
cancer
subject
compound
pharmaceutical composition
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565466A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022229907A5 (https=
JP2024515215A5 (https=
Inventor
ミュラー、トーマス
メーラー、ハンス
コスティン、ジェイムズ・シー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geistlich Pharma AG
Original Assignee
Geistlich Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma AG filed Critical Geistlich Pharma AG
Publication of JP2024515215A publication Critical patent/JP2024515215A/ja
Publication of JPWO2022229907A5 publication Critical patent/JPWO2022229907A5/ja
Publication of JP2024515215A5 publication Critical patent/JP2024515215A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023565466A 2021-04-29 2022-04-28 抗菌剤及び抗癌剤 Pending JP2024515215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181492P 2021-04-29 2021-04-29
US63/181,492 2021-04-29
PCT/IB2022/053973 WO2022229907A1 (en) 2021-04-29 2022-04-28 Antimicrobial and anticancer agents

Publications (3)

Publication Number Publication Date
JP2024515215A true JP2024515215A (ja) 2024-04-05
JPWO2022229907A5 JPWO2022229907A5 (https=) 2025-04-30
JP2024515215A5 JP2024515215A5 (https=) 2025-04-30

Family

ID=81598080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565466A Pending JP2024515215A (ja) 2021-04-29 2022-04-28 抗菌剤及び抗癌剤

Country Status (8)

Country Link
EP (1) EP4330238A1 (https=)
JP (1) JP2024515215A (https=)
KR (1) KR20240004303A (https=)
CN (1) CN117295720A (https=)
AU (1) AU2022267897A1 (https=)
CA (1) CA3216783A1 (https=)
IL (1) IL307990A (https=)
WO (1) WO2022229907A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202448502A (zh) * 2023-02-20 2024-12-16 日商大鵬藥品工業股份有限公司 Ftd・tpi調配劑、pd-1路徑拮抗劑、及vegf路徑拮抗劑之併用
WO2026074499A1 (en) * 2024-10-03 2026-04-09 Geistlich Pharma Ag Methods and compositions for inhibiting c-myc

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150182534A1 (en) * 2012-06-18 2015-07-02 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
JP2018502909A (ja) * 2014-12-19 2018-02-01 ガイストリッヒ・ファルマ・アーゲーＧｅｉｓｔｌｉｃｈ Ｐｈａｒｍａ Ａｇ オキサチアジン様化合物を作製する方法
WO2020234828A1 (en) * 2019-05-22 2020-11-26 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1160443B (de) * 1961-11-30 1964-01-02 Hoechst Ag Verfahren zur Herstellung von Tetrahydro-oxathiazin-dioxyden
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150182534A1 (en) * 2012-06-18 2015-07-02 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
JP2018502909A (ja) * 2014-12-19 2018-02-01 ガイストリッヒ・ファルマ・アーゲーＧｅｉｓｔｌｉｃｈ Ｐｈａｒｍａ Ａｇ オキサチアジン様化合物を作製する方法
WO2020234828A1 (en) * 2019-05-22 2020-11-26 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh

Also Published As

Publication number Publication date
KR20240004303A (ko) 2024-01-11
US20240199563A1 (en) 2024-06-20
EP4330238A1 (en) 2024-03-06
WO2022229907A1 (en) 2022-11-03
CN117295720A (zh) 2023-12-26
AU2022267897A1 (en) 2023-11-02
CA3216783A1 (en) 2022-11-03
IL307990A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
JP7688098B2 (ja) オキサチアジン様化合物を作製する方法
US20120316203A1 (en) Compositions and Methods for Inhibition of Cancers
EP3188721B1 (en) Human therapeutic agents
EP2861573B1 (en) Oxathiazine derivatives as antibacterial and anticancer agents.
JP6929234B2 (ja) 医薬共結晶組成物及びその用途
JP2024515215A (ja) 抗菌剤及び抗癌剤
US12534443B2 (en) Processes for preparing oxathiazin-like compounds
EP3429582B1 (en) Combination therapy for proliferative diseases
US12612375B2 (en) Antimicrobial and anticancer agents
WO2009105936A1 (zh) 苯酚苷衍生物在制备抗细胞增生疾病组合物中的应用
WO2022028615A1 (zh) 治疗肿瘤的方法
WO2024028847A1 (en) Combination therapy for treating cancers
CN110025617B (zh) 双去甲基汉防己甲素双甲酸乙酯与酪氨酸激酶抑制剂的药物组合物
US20260021106A1 (en) Combination therapy for treating cancers
CN113993515B (zh) 使用藏红花酸治疗实体肿瘤的方法
KR20110045303A (ko) 클로로퀸 또는 바필로마이신과 항암제를 포함하는 항암제 조성물
JP5955531B2 (ja) 抗癌剤
TWI401085B (zh) Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents
WO2024123412A1 (en) Ferroptosis inducers to treat cancer
HK40076913A (en) Processes for preparing oxathiazin-like compounds
WO2025229179A1 (en) Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer
KR20060136219A (ko) 시스플라틴과 녹차 추출물을 포함하는 항암 조성물
KR20060007368A (ko) Ｎ-(3-클로로-1ｈ-인돌-7-일)-4-설파모일벤젠설폰아미드를포함하는 약제 조성물 및 세포 증식 억제제
KR20070000249A (ko) 시스플라틴과 녹차 추출물을 포함하는 항암 조성물
MX2007003215A (es) Cromaderivados, medicamentos y su uso en terapias.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225